Touchstone Sands Capital US Select Growth ETF (TSEL)

SpyGlass Pharma, a private ophthalmic biotech company, raised $75 million in Series D funding to advance its drug delivery platform for glaucoma treatment through Phase III trials. The platform aims to provide multiple years of therapy, addressing the need for long-term management of chronic eye diseases.